KV’s SITE RELEASE® drug delivery system provides a creative, unique approach to drug delivery, combining bioadhesion to wet living tissues with controlled release of the drug agent. Products incorporating SITE RELEASE® technology are designed to adhere to wet living tissues, yet are minimally affected by the presence of moisture.
SITE RELEASE® is currently commercialized in two Ther-Rx Corporation products, Gynazole-1® and Clindesse®, thus providing one-dose-to-treat products, with a potential to improve patient compliance, while also allowing anytime dosing with minimized leakage. SITE RELEASE® butoconazole nitrate 2% vaginal cream, used in Gyanazole-1® and clindamycin phosphate 2% vaginal cream used in Clindesse® have both received FDA approval.
Click here to review our Technology Evaluation: Advancing Vaginal Drug Delivery |
|
|
|